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Cross-reactive immunity against the SARS-CoV-2
Omicron variant is low in pediatric patients with
prior COVID-19 or MIS-C
Juanjie Tang1,31, Tanya Novak 2,3,31, Julian Hecker4,31, Gabrielle Grubbs 1,31, Fatema Tuz Zahra1,
Lorenza Bellusci1, Sara Pourhashemi1, Janet Chou5,6, Kristin Mofﬁtt5,7, Natasha B. Halasa8,
Stephanie P. Schwartz9, Tracie C. Walker9, Keiko M. Tarquinio10, Matt S. Zinter 11, Mary A. Staat12,
Shira J. Gertz13, Natalie Z. Cvijanovich14, Jennifer E. Schuster15, Laura L. Loftis16, Bria M. Coates17,
Elizabeth H. Mack18, Katherine Irby 19, Julie C. Fitzgerald20, Courtney M. Rowan 21, Michele Kong22,
Heidi R. Flori23, Aline B. Maddux24, Steven L. Shein 25, Hillary Crandall 26, Janet R. Hume27,
Charlotte V. Hobbs28, Adriana H. Tremoulet29, Chisato Shimizu 29, Jane C. Burns29, Sabrina R. Chen2,
Hye Kyung Moon2, Christoph Lange30, Adrienne G. Randolph 2,3,5,32 & Surender Khurana 1,32 ✉

Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in
children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing
capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by agestratiﬁed analyses (<5, 5–11, 12–21 years) in 177 pediatric patients hospitalized with severe
acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody
titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19
have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years
of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate
higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and
adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated
twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These
ﬁndings can inﬂuence transmission, re-infection and the clinical disease outcome from
emerging SARS-CoV-2 variants and supports the need for vaccination in children.

A full list of author afﬁliations appears at the end of the paper.
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evere acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection in children and adolescents is usually
asymptomatic or causes mild disease, however, they can
develop severe manifestations of coronavirus disease 2019
(COVID-19) and are at risk for developing a post-infectious
complication called multisystem inﬂammatory syndrome in
children (MIS-C). As of February 2022, the World Health
Organization had deﬁned ﬁve SARS-CoV-2 variants of concern
(VOCs) named Alpha, Beta, Gamma, Delta, and Omicron. The
SARS-CoV-2 Omicron variant contains >30 mutations in
the SARS-CoV-2 spike protein, allowing rapid spread around the
globe, and resulting in large outbreaks in children and
adolescents1–6. Studies in adults show the SARS-CoV-2 Omicron
variant is resistant to neutralizing antibodies after a prior SARSCoV-2 infection or current SARS-CoV-2 vaccines2,7–9.
As of February 2022, children below 5 years are ineligible to
receive SARS-CoV-2 vaccination, while those in the age group of
5–11 are eligible to receive 2 vaccine doses and adolescents 12 years
and older can get a 3rd vaccine dose in the US. Children are highly
impacted by the Omicron outbreak. Despite availability of vaccine
for children 5 years and over, vaccination rates remain low especially
in patients that developed multisystem inﬂammatory syndrome in
children (MIS-C) related to SARS-CoV-210. Therefore, most children remain susceptible to SARS-CoV-2 infection by emerging
SARS-COV-2 variants especially with the highly transmissible
Omicron variant11, and can potentially transmit to other children
and vulnerable populations12. Limited knowledge exists regarding
SARS-CoV-2 antibody responses in children. Recent studies evaluated immune response following SARS-CoV-2 infection in convalescent children13 or asymptomatic group14, and did not age
stratify children and did not discover age-related differences in different disease cohorts, including acute, severe hospitalized COVID19 and MIS-C. The antibody response in adults demonstrates
diminished ability to neutralize Omicron and other VOCs, but the
antibody response in age-stratiﬁed children with different diseases
categories to VOCs is unclear8,9,15,16.
In this study, we evaluated neutralization capacity of serum/
plasma samples from three independent pediatric disease cohorts
against the SARS-CoV-2 at the time of sample collection and ﬁve
VOCs: Alpha (B.1.1.7), Gamma (P.1), Beta (B.1.351), Delta
(B.1.617.2), and Omicron (B.1.1.529), that were not widely circulating in U.S. The three independent cohorts included children
and adolescents with a range of disease severity including patients
hospitalized with acute COVID-19 or MIS-C, and convalescent
samples from pediatric outpatients who initially had mild
COVID-19. To assess the inﬂuence of age on the immune
response, pediatric cohorts were stratiﬁed into <5 years, 5–11
years, and 12–21 years, based on current age stratiﬁcations for
SARS-CoV-2 vaccines in the U.S.
Results
Antibody proﬁling was performed on the samples from 177 children hospitalized with either acute COVID-19 or MIS-C, or outpatient mild convalescent COVID-19 (Fig. 1a and Supplementary
Tables S1 and S2). Children <5 years old hospitalized with acute
COVID-19 had signiﬁcantly less ICU admissions compared to
MIS-C patients (p = 0.02) (Fig. 1b). Acute children <5 years old
also required signiﬁcantly less respiratory support than older
children (12–21) with the same acute illness (p = 0.05). There were
no differences in disease severity based on ICU admission,
respiratory support, or mechanical ventilation among different
MIS-C age groups. None of these children were vaccinated.
SARS-CoV-2 WA1 nucleocapsid binding IgG were observed in
all the 177 SARS-CoV-2 infected children (Fig. 1c). In children
hospitalized with acute COVID-19, an age-stratiﬁed nucleocapsid
2

binding IgG titer was observed, with younger children (<5 years
old) showing lower nucleocapsid IgG compared with older children (≥5 years). No age difference was observed for nucleocapsid
IgG in children with either outpatient mild convalescent COVID19 or with MIS-C. Younger children (<5 years) with convalescent
COVID-19 or MIS-C demonstrated higher nucleocapsid IgG
titers compared with <5 years children with acute COVID-19.
Pseudovirion neutralization assay (PsVNA) was used to measure the antibody neutralization activity of the children’s samples
against the predominant SARS-CoV-2 WA1 strain and the ﬁve
VOCs (Supplementary Table S3). SARS-CoV-2 neutralizing
activity measured by this qualiﬁed PsVNA correlated with PRNT
(plaque reduction neutralization test with authentic SARS-CoV-2
virus) in previous studies17,18. As a control, samples from 10
critically ill children positive for seasonal coronaviruses collected
prior to 2019 did not demonstrate neutralization titers against
SARS-CoV-2 (Source Data ﬁle).
The 177 post-SARS-CoV-2 infection samples demonstrated
variable PsVNA50 titers (ranged from 1:10 to 1:24,430 for a
sample dilution that resulted in 50% virus neutralization) against
ancestral WA1 strain (Fig. 2 and Supplementary Fig. S1). A
steady increase of neutralizing antibodies was observed as age
increased from young children (<5 years) with geometric mean
titers (GMT) of 1:32 to 1:260 for adolescents (12–21 years)
against the ancestral WA1 strain (Fig. 2a) in children with acute
COVID-19. Adolescents (aged 12–21) with acute COVID-19
showed 4.4 to 8.1-fold higher WA1 neutralization GMT compared with patients ≤11 years of age. However, samples from
inpatients hospitalized with MIS-C or convalescent samples from
non-hospitalized outpatient children that recovered from mild
COVID-19 (Convalescent COVID-19), demonstrated an increase
in WA1 neutralizing antibodies in younger children such that
PsVNA50 titers were similar across all age groups (Fig. 2b, c, and
Supplementary Figs. S1a–c and S2b, c). In younger patients
(≤11 years old), as expected, those with MIS-C (GMT from 1:600
to 1:766) or convalescent COVID-19 (GMT from 1:450 to 1:513)
demonstrated 13 to 19-fold higher PsVNA50 GMT against WA1
than children with acute COVID-19 (GMT from 1:32 to 1:59)
(Fig. 2 and Supplementary Fig. S2a, b).
For the acute COVID-19 patients, neutralization titers against
VOCs demonstrated a similar age-stratiﬁed trend from low
PsVNA50 titers in younger children (<5 years) to higher titers in
adolescents (Fig. 2a). In contrast to PsVNA50 titers against WA1,
neutralization of the ﬁve VOCs was signiﬁcantly reduced across
all age groups (Supplementary Fig. S1a). The highest reduction in
PsVNA50 titers was observed against Omicron such that none (0/
36) of the younger children (≤11 years; GMT of 1:10) and only 2/
26 adolescents (12–21 years; GMT of 1:12) demonstrated
PsVNA50 titers above the seropositive cut-off of PsVNA50 titer
of 1:20 against Omicron (Fig. 2a and Supplementary Fig. S1a).
For convalescent COVID-19 patients, although neutralization
titers against WA1 among the age groups were comparable (GMT
of 1:450 to 1:513), an age-dependent trend of decreasing neutralization titers was observed against Delta and Beta VOCs, with
~2-fold higher GMT in younger children (<5 years) compared
with adolescents (Fig. 2b). Similar to WA1, neutralization titers of
VOCs were signiﬁcantly higher in convalescent individuals than
acute-COVID-19 patients for younger children (≤11 years) but
not in adolescents (12–21 years) (Supplementary Fig. S2). The
greatest reduction in PsVNA50 titers compared with WA1 was
observed against Omicron (32–41-fold), followed by Beta (4–7fold) and then Delta (3–6-fold) across all convalescent COVID-19
age groups (Supplementary Fig. S1b). Most importantly, only
16% (8/50) convalescent children across age groups demonstrated
seropositivity (PsVNA50 > 1:20) against Omicron (PsVNA50
ranging from 1:10 to 1:127) (Fig. 2b).
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For MIS-C patients, there was a consistent drop in neutralization titers against VOC with similar patterns across all ages
(Fig. 2c and Supplementary Fig. S1c). Moreover, in children ≤11
years old, similar to WA1, the absolute PsVNA50 titers against
the ﬁve VOC in MIS-C patients demonstrated higher neutralizing
titers compared with acute COVID-19 patients, but not in adolescents (Supplementary Fig. S2c). The antibody response of the
MIS-C patients and those with convalescent COVID-19 were
similar across age groups.
Antigenic cartography was performed to explore how the different age and disease categories in these pediatric cohorts distinguish neutralization of the SARS-CoV-2 variants (Fig. 3). For

acute COVID-19, the variants were tightly clustered closer to the
ancestral WA1 strain in younger children (≤11 years), while the
distribution was more heterogeneous for acute COVID-19 adolescents, especially with distance between WA1 and Omicron.
Across all age groups, the convalescent COVID-19 and MIS-C
samples were heterogenous with Alpha, Gamma, and Delta VOCs
clustered around WA1, with small distance between WA1 and
Beta for convalescent COVID-19 (5 years and above) and all
MIS-C patients. The antigenic distances between Omicron and
WA1 were large for all convalescent COVID-19 and MIS-C
across all age cohorts, in agreement with the neutralization titers
observed in Fig. 2.
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Fig. 1 Study design and demographics of children with acute COVID-19 or convalescent COVID-19 or MIS-C and adults with acute COVID-19 and
controls. a Overview of pediatric cohort, including control (seasonal human coronavirus positive but SARS-CoV-2 negative collected before 2019) and
children with acute COVID-19 or convalescent COVID-19 or MIS-C. b Percent distribution of hospitalized acute COVID-19 and MIS-C patients admitted to
the intensive care unit (ICU), requiring any respiratory support, and receiving mechanical ventilation. c SARS-CoV-2 WA1/2020 nucleocapsid binding
antibodies in SARS-CoV-2 infected children from either acute COVID-1, convalescent COVID-19 or MIS-C for toddlers (<5 years; in red), pediatric (5–11
years; in blue), or adolescents (12–21 years; in orange). Each serum sample was evaluated in IgG-ELISA in duplicate to determine the nucleocapsid-binding
IgG end-point titer. The height of bars and numbers over the bars indicate the IgG GMTs, and the whiskers indicate 95% conﬁdence intervals. Statistical
differences between age groups within each disease category or between different disease category within each age group were analyzed by R and the twosided statistically signiﬁcant p-values are shown. The p-values are not corrected for multiple comparisons. Source data are provided as a Source Data ﬁle.

Although we do not have serial samples on all hospitalized
acute COVID-19 patients, it is possible that the younger children
hospitalized with COVID-19 had a less robust neutralizing
antibody response due to lower disease severity, which likely
improved during convalescence (convalescent COVID-19, or
MIS-C which presents weeks after initial infection), such that
their capacity to neutralize the ancestral SARS-CoV-2 WA1 strain
and the Alpha, Beta, Gamma, and Delta VOCs is similar to
adolescents with COVID-19 or MIS-C. Importantly, a majority
(>90%) of the children evaluated in this study did not demonstrate neutralizing antibodies against the Omicron variant.
To determine if vaccination of naïve (SARS-CoV-2 negative)
adolescents leads to greater cross-neutralization of VOCs
including Omicron, we evaluated neutralizing antibody response
in a comparator group of children (median age of 16.9 years;
range 15.9–19.0 years) who were vaccinated with two doses of
either Pﬁzer (BNT16b2) or Moderna mRNA vaccine (n = 7) or a
single dose of either Pﬁzer or Moderna (n = 2). Serum samples
were obtained between 19 and 163 days (median of 50 days) after
vaccination. In contrast to SARS-CoV-2 infection, children vaccinated once or twice demonstrated higher titers against vaccinehomologous WA1 strain (GMT 1:1888) as well all ﬁve VOCs,
Alpha, Beta, Gamma, Delta, and Omicron (Fig. 4). Largest
reduction (25.2-fold) of neutralization titers in vaccinated children was observed against the Omicron variant, however,
importantly, all 8 of the 9 children who received two doses of
mRNA vaccine still showed PsVNA50 titers >1:20 against
Omicron.
Discussion
Understanding the pediatric antibody response against SARSCoV-2 Omicron and emerging variants is critical for disease
management, development of therapeutics, and reﬁnement of
vaccines in this under-studied population. This study of children
and adolescents ≤21 years old that were previously infected with
SARS-CoV-2 between April 2020 and March 2021 revealed an
age-dependent effect in the neutralization of ﬁve different SARSCoV-2 VOCs. The most prominently reduced antibody
neutralization occurred in the youngest children with acute
COVID-19 compared with older age groups. MIS-C patients and
convalescent outpatients who had mild COVID-19 showed
similar responses across all ages. Overall, results suggest a differentially evolving quantitative and qualitative neutralizing
response to SARS-CoV-2 and VOCs in children less than 5 years
old and who are currently ineligible for vaccination. This is
especially important as children in this study were infected with
SARS-CoV-2 prior to the circulation of Delta or Omicron did not
have neutralizing antibodies against Omicron and therefore are
likely susceptible to re-infection with the Omicron variant.
During acute COVID-19, an age-dependent increase in neutralizing antibodies against SARS-CoV-2 WA1 and VOC was
observed from young children to adolescents. Recently, cellular
immune proﬁling demonstrated that systemic immune response
in the blood of children is characterized by a more naive state
4

compared with a more memory-based immune repertoire in
adults19. Since younger children (<5 years) have lower percentages of memory B cells than adolescents, they generate a primary
immune response after SARS-CoV-2 infection, which develops
slower than a recall response, as was observed for lower antibodies during acute COVID-19 in younger children (<5 years).
The timeframe of symptom onset was also considered in
understanding the acute immune response. In our acute COVID19 cohort, the median timeframe between symptom onset and
their sample being collected was 3 days (IQR 2, 6 days) for
children <5 years old, 3.5 days (IQR 2, 5 days) for children 5–11
years old, and 6 days (IQR 2, 10 days) for adolescents giving the
older children only a slightly longer timeframe to start producing
antibodies, although there was no signiﬁcant difference (p value
of 0.2–1.0) between different age cohorts.
During post-infectious MIS-C or convalescence COVID-19,
children of all ages demonstrated similar neutralization capacity to
the WA1 strain, however, the GMT against the Beta and Delta
VOC were higher in younger children (<5 years) compared with
convalescent COVID-19 adolescents (12–21 years). One possible
explanation for these qualitative antibody differences against
VOCs during convalescent COVID-19 between age groups could
be due to the original antigenic sin (OAS) hypothesis, whereby
older children have B-cell memory due to prior exposure to seasonal coronaviruses, especially in SARS-CoV-2 spike S2 domain as
observed in older children, adults, and elderly20–23. Recently, we
observed anti-S2 cross-reactivity in naive older children but not in
the younger children (<4 years old), who share homology with
HKU1, 229E, and OC4323,24. OAS was also observed in mice
immunization studies with seasonal CoV followed by SARS-CoV2 spike25. Most of these cross-reactive antibodies do not neutralize
SARS-CoV-2, as was observed with samples from 10 children with
seasonal CoVs in our study. It is expected that cross-reactive
memory B cells will be recalled shortly after SARS-CoV-2 infection (likely with a WA1 or Alpha-like strain in this cohort) primarily in immune-exposed older children, that results in a more
focused recall antibody response, which potentially diminishes the
immune system’s ability to recognize and neutralize SARS-CoV-2
variants like Beta and Delta in older children. Since immune
system in younger children (<5 years) is more naive than adolescents, they generate a more diverse primary antibody response
following SARS-CoV-2 infection, which demonstrates a robust,
broad anti-SARS-CoV-2 immunity capable of effectively neutralizing variants like Beta and Delta.
We evaluated the convalescent antibody response in children
under 5 years old who presented with mild symptoms of SARSCoV-2 infection or were asymptomatic and tested PCR positive
after a family member was infected. These patients were recruited
as a control group for those at risk of MIS-C. Our study showed
that these young children without access to COVID-19 vaccination had a robust antibody response against most SARS-CoV-2
variants during convalescence. These samples came from time
periods prior to circulation of Delta or Omicron variants in the
US and vaccines were not available for adolescents, so patients

NATURE COMMUNICATIONS | (2022)13:2979 | https://doi.org/10.1038/s41467-022-30649-1 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-30649-1

ARTICLE

SARS-CoV-2 Neutralizing Antibody (PsVNA50)

a

b

c

Fig. 2 Neutralizing antibody titers of serum/plasma from children with COVID-19 or MIS-C against SARS-CoV-2 WA1 and VOCs. a–c Geometric mean
titer (GMT) values ± 95% conﬁdence interval for pseudovirus neutralization assay (PsVNA) neutralization titers (PsVNA50; 50% virus neutralization
titers) for serum/plasma from 177 children with either acute COVID-19 (a), convalescent COVID-19 (b) or inpatients with MIS-C (c), against ancestral
SARS-CoV-2 WA1 and VOCs: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529) for toddlers (<5 years; in red),
pediatric (5–11 years; in blue), adolescents (12–21 years; in orange) with COVID-19 or MIS-C as determined by PsVNA in 293-ACE2-TMPRSS2 cells. GMT
values for PsVNA50 titers are color coded for each of the age group. The horizontal dashed line indicates the limit of detection for the neutralization assay
(PsVNA50 of 1:20). The samples that did not neutralize SARS-CoV-2 at 1:20 serum dilution was given a PsVNA50 value of 10 for graphic representation
and statistical analysis. The PsVNA is a qualiﬁed assay where all samples are run with a set of internal standards in every plate of the neutralization assay
and conforms with assay performance. All PsVNA experiments were performed in duplicate and the researchers performing the assay were blinded to
sample identity. The variations for duplicate runs were <7%. The data shown are average values of two experimental runs. Statistical differences were
analyzed in R (version 4.1.2) using a permutation-based approach and the two-sided statistically signiﬁcant p-values are shown. The p-values are not
corrected for multiple comparisons. Source data are provided as a Source Data ﬁle.
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Fig. 3 Antigenic cartography of different age group children with acute COVID-19 vs convalescent COVID-19 vs MIS-C against SARS-CoV-2 WA1 and
ﬁve VOCs. Individual antigenic maps were generated for each disease cohort in young children (<5 years), school-age children (5–11 years), and
adolescent (12–21 years), with either acute COVID-19 (a), convalescent COVID-19 (b) or MIS-C (c), against SARS-CoV-2 WA1 (blue) or the VOCs Alpha
(light orange circle), Beta (green circle), Gamma (brown circle), Delta (black circle) and Omicron (red circle). Black diamonds correspond to each
individual sera/plasma. Each grid square corresponds to 2-fold dilution in the neutralization assay. Source data are provided as a Source Data ﬁle.

were highly unlikely to be exposed to these variants and were not
administered SARS-CoV-2 vaccine. The MIS-C cohort, which is
also a post-infectious convalescent state and rare complication,
showed a similar pattern to that of the convalescent patients who
did not develop MIS-C. The majority of MIS-C patients were in
the ICU requiring respiratory support at the time the sample was
taken, but despite this, their antibody response was very similar to
that of the convalescent children with mild disease who were
never hospitalized. And although IVIG was administered to an
average of 59.8% MIS-C patients before samples were collected,
their antibody levels were similar to those in convalescent
COVID-19 patients and are not thought to impact the results. To
support this, our previous studies have shown that IVIG produced by US manufacturers up to March 2021 did not contain
anti-SARS-CoV-2 antibodies since they were made from plasma
collected prior to 202017.
To our knowledge, this is the ﬁrst evaluation of antibody
response to Omicron in convalescent COVID-19 and MIS-C
pediatric patients, who are potentially at risk of re-infection with
6

Omicron or newly emerging SARS-CoV-2 variants, as has been
observed in adults26. A signiﬁcant strength of this study is that
the pediatric acute and MIS-C samples were from a U.S. national
multicenter cohort collected during the pandemic, increasing
generalizability. All samples were collected between April 2020
and March 2021. In the US, the WA1 strain had been circulating
since January 2020 and as of 11 March 2021, the majority of
emerging VOC cases were due to the Alpha strain, followed by
108 cases of Beta, and only 17 cases of Gamma27. One study
limitation is that we do not have patients’ SARS-CoV-2 viral
sequencing to verify or explain the variability of the different
pediatric age groups in successfully neutralizing the SARS-CoV-2
variants. Lastly, since the acute COVID-19 and MIS-C patients
were hospitalized, we chose to statistically control for disease
severity when comparing antibody levels. Another limitation is
cohort of vaccinated children is small, as well as skewed towards
the older (>15) age group. However, the neutralizing antibody
response measured in our study mimics to those observed in
younger children against the vaccine-matched strain28.
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50% Neutralization titer

Neutralization Assay of vaccinated children serum (n=9)

Fig. 4 Neutralization by post-vaccination serum from children against
SARS-CoV-2 WA1/2020 strain and variants of concern. Serum samples
following one (n = 2) or two (n = 7) doses of SARS-CoV-2 mRNA vaccine
were obtained from nine healthy children without any co-morbidities.
Neutralization assays were performed with the use of pseudoviruses
harboring the SARS-CoV-2 spike proteins of the WA1/2020 vaccine strain
or VOCs: Alpha, Beta, Gamma, Delta, or the Omicron variants. The assay of
each individual sample (circles) was performed in duplicate to determine
the 50% neutralization titer against the indicated pseudovirus. One child
who got only a single vaccination is shown as an open symbol. The heights
of the bars and the numbers over the bars indicate the geometric mean
titers, and the whiskers indicate 95% conﬁdence intervals. The numbers in
parentheses indicate the average decrease in neutralization titer of the
indicated variants as compared with that of the WA1/2020 virus. The
horizontal dashed line indicates the limit of detection for the neutralization
assay (PsVNA50 of 20). Differences between SARS-CoV-2 strains were
analyzed by R and the two-sided statistically signiﬁcant p-values are shown.
The p-values are not corrected for multiple comparisons. Source data are
provided as a Source Data ﬁle.

In conclusion, our ﬁndings suggest that the antibodies produced
by previous SARS-CoV-2 infection in pediatric population do not
neutralize the currently circulating Omicron variant and therefore
they potentially remain susceptible to re-infection with Omicron.
Vaccine induced a much broader neutralizing antibody response
against VOCs in naïve children compared with the natural immunity
induced following SARS-CoV-2 infection. Our study highlights a
decrement in the antibody response to VOCs in children after natural
infection that was most striking for the Omicron variant whereas the
breadth of the antibody response was more robust in a control group
of vaccinated children. Despite availability in the U.S. since October
2021, vaccine uptake in children ages 5–11 years is overall low as of
March 202210. Our study highlights the importance of vaccinating
children and younger adolescents even with preexisting antibody
immunity by an earlier SARS-CoV-2 strain to prevent severe disease
in children from Omicron and future infections28–30. These ﬁndings
have direct implications for developing age-targeted strategies for
testing, disease mitigation, vaccination, and protecting this vulnerable
population.
Methods
Study design. The objective of this study was to investigate the neutralizing
capacity of serum or plasma from children of age-stratiﬁed groups with acute
hospitalized COVID-19 or mild outpatient convalescent COVID-19 or hospitalized
MIS-C with SARS-CoV-2 VOCs: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1),
Delta (B.1.617.2), and Omicron (B.1.1.529).
The 177 U.S. pediatric patients (mean age 9 years [IQR 3.6, 14.8 years]) enrolled
comprised 3 independent cohorts: 62 hospitalized with acute COVID-19, 65
hospitalized with MIS-C, and 50 non-hospitalized children with mild COVID-19 with
convalescent samples (≥30 days post-acute) enrolled as an at-risk for MIS-C control
group (Fig. 1). MIS-C and acute COVID-19 were deﬁned using U.S. Centers for

Disease Control and Prevention (CDC) case deﬁnitions (criteria listed below). Patients
were <5 years (n = 62: 22 acute COVID-19, 14 convalescent COVID-19, 26 MIS-C),
5–11 years (n = 50: 11 acute COVID-19, 17 convalescent COVID-19, 22 MIS-C),
and 12–21 years old (n = 65: 22 acute COVID-19, 20 convalescent COVID-19, 23
MIS-C). All acute and convalescent COVID-19 pediatric patients had SARS-CoV-2
detected by reverse transcriptase quantitative PCR (RT-qPCR) and MIS-C patients
had positive SARS-CoV-2 antibody and/or RT-qPCR tests. Demographic, clinical and
laboratory data are summarized in Tables S1 and S2. Samples from the three pediatric
cohorts (acute COVID-19 vs convalescent COVID-19 vs MIS-C) were collected from
a prospectively enrolling multicenter study (Overcoming COVID-19). Children’s
acute COVID-19 samples (serum or plasma) were collected as early as possible during
hospitalization and/or study enrollment.
MIS-C is a hyperinﬂammatory syndrome that occurs ~3–6 weeks post-SARSCoV-2 infection in children and patients in this cohort were asymptomatic or had
mild illness upon initial infection. As a control group for MIS-C, we collected
samples from outpatient children and adolescents with a positive PCR test for
SARS-CoV-2 and asymptomatic or mild illness (never hospitalized) ~3–6 weeks
after their positive test. Because MIS-C is rare (~2–3 per 10,000 SARS-CoV-2
infections in US) and it not possible to identify patients in advance, it is not feasible
to get baseline (during initial infection) samples in most MIS-C patients31.
Serum samples were also obtained from 9 naïve (SARS-CoV-2 negative)
children (16.9 years median age; age range 15.9–19.0 years) who were vaccinated
with one or two doses of Pﬁzer (BNT16b2) (n = 7) or Moderna (n = 2) mRNA
vaccine. Samples were collected between 19 and 163 days (median of 50 days) postvaccination from these children.
Clinical study and case deﬁnitions. The Overcoming COVID-19 Network studies
severe complications of COVID-19 in children and adolescents and their public
health surveillance work has been described previously32; a subgroup of 20 sites in
18 U.S. states participate in the Overcoming COVID-19 Immunobiology Study.
Study sites relied on a single IRB at Boston Children’s Hospital under Protocol
Number #IRB-P00033157, and informed consent was obtained from at least one
parent or legal guardian. Samples from the Boston Children’s Hospital COVID-19
Biobank Taking on COVID-19 Together Protocol included consented patient
samples and de-identiﬁed samples obtained with IRB-approved waiver of consent
under #IRB-P00035409. Seasonal coronavirus controls samples were from studies
prior to the COVID-19 pandemic33.
All pediatric patients were <21 years old with conﬁrmed SARS-CoV-2 positive
PCR or antibody testing. Patients with immune compromising conditions that
could impair antibody responses were excluded, as were patients with life support
limitations or end stage lung disease. Hospitalized patients with COVID-19-related
complications were hospitalized for acute COVID-19 or MIS-C as deﬁned below
and samples were collected acutely as early into their hospital course as possible.
Convalescent patients were outpatient SARS-CoV-2 PCR positive patients with
mild or no symptoms, presenting to the Emergency Department or clinics afﬁliated
with Boston Children’s Hospital who returned for a blood draw approximately 4-6
weeks later. Data collection included demographic information including race and
ethnicity, past medical history including chronic health conditions, SARS-CoV-2
testing results, clinical diagnosis of acute COVID-19 or MIS-C, and hospital course
including discharge outcome.
Clinical cohorts. In this study, 62 pediatric patients were hospitalized with acute
COVID-19. This was deﬁned as having signs or symptoms that could be associated
with early SARS-CoV-2 infection accompanied by a positive real-time polymerase
chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) as deﬁned by the U.S. Centers for Disease Control and Prevention
(CDC) as listed on their website (https://wwwn.cdc.gov/nndss/conditions/
coronavirus-disease-2019-covid-19/case-deﬁnition/2020/ approved 5 April 2020).
●

●
●

At least two of the following symptoms: fever (measured or subjective),
chills, rigors, myalgia, headache, sore throat, new olfactory, and taste
disorder(s); AND
At least one of the following symptoms: cough, shortness of breath, or
difﬁculty breathing; OR
Severe respiratory illness with at least one of the following:
Clinical or radiographic evidence of pneumonia, OR
Acute respiratory distress syndrome (ARDS).

●

AND
No alternative more likely diagnosis

MIS-C patients met the criteria for Multisystem Inﬂammatory Syndrome in
Children as deﬁned by the CDC32 as listed on their website (https://www.cdc.gov/
mis-c/hcp/ published 5/14/2021) including:
●

An individual aged <21 years presenting with fever*, laboratory evidence of
inﬂammation**, and evidence of clinically severe illness requiring
hospitalization, with multisystem (≥2) organ involvement (cardiac, renal,
respiratory,
hematologic,
gastrointestinal,
dermatologic
or
neurological); AND
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No alternative plausible diagnoses; AND
Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology,
or antigen test; or exposure to a suspected or conﬁrmed COVID-19 case
within the 4 weeks prior to the onset of symptoms.
*Fever ≥38.0° C for ≥24 h, or report of subjective fever lasting ≥24 h
**Including, but not limited to, one or more of the following: an elevated
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ﬁbrinogen,
procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or
interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes, and low
albumin

Convalescent COVID-19 samples were collected from outpatients presenting to
the emergency department or clinics between approximately 1–3 months after
initial positive SARS-CoV-2 RT-PCR who had asymptomatic SARS-CoV-2
infection or mild acute COVID-19 infection (received no oxygen or other support)
at the time of the positive PCR. Patients that later met criteria for MIS-C or
developed acute COVID-19 were excluded from this cohort. Patients were never
hospitalized for SARS-CoV-2-related complications prior to obtaining the
convalescent sample.
Specimen collection and processing. Acute COVID-19 pediatric samples were
collected between days 0–12 of a positive SARS-CoV-2 test (median 1 day, IQR 1,
3 days). MIS-C patient samples were collected between days 0–17 of hospitalization
(median 2 days, IQR 1, 3 days). Convalescent pediatric samples were collected
between days 30–110 after their positive PCR test (median 59 days, IQR 50,
77 days). Pediatric samples were collected April 2020 through March 2021 (see
Table S2).
Fresh blood was collected into sodium heparin, EDTA, or no additive
vacutainers and centrifuged at 1300 x g (RCF) for 10 min at room temperature.
Plasma or serum was aliquoted and frozen at −80 °C. If a fresh blood sample was
not obtained upon enrollment, residual specimens from clinical testing (lithium
heparin plasma or serum) were retrieved. Samples were heat-treated at 56 °C for
1 h and refrozen at −80 °C prior to assay.

with PBS/0.05% Tween 20, bound human IgG antibodies were detected with 1:5000
dilution of HRP-conjugated anti-human IgG Fc-speciﬁc antibody (Jackson
Immuno Research). After 1 h, plates were washed PBST followed by PBS, and
o-Phenylenediamine dihydrochloride (OPD) was added for 10 min. Absorbance
was measured at 492 nm. End-point titer was determined as 2-fold above the
average of the absorbance values of the binding of serum samples to blank control
wells. The end-point titer is reported as the serum dilution that was above this
cutoff and was calculated using Prism 9 (GraphPad Software).
Statistical analysis. All experimental data were analyzed using R statistical software (version 4.1.2). Absolute measurements were log2-transformed prior to
analysis. The statistical analysis tested for signiﬁcant differences in neutralization
titer measurements between (a) different age groups (<5 years old, 5–11 years old,
and 12–21 years old) within a ﬁxed patient disease category (acute COVID-19,
convalescent COVID-19, and MIS-C), (b) different patient disease categories
within a ﬁxed age group, and (c) between variants/mutations within a ﬁxed age and
disease category group. Statistical signiﬁcance was assessed based on permutation
testing, avoiding distribution assumptions about the (log) titer measurements36.
For the tests between age groups and disease categories, log titer measurements
were permuted between the samples in the respective groups/categories. For the
tests between variants/mutations, log titer measurements were randomly reassigned to variants/mutations within samples. Two-sided empirical p-values were
estimated as the proportion of 1,000,000 random permutations with larger absolute
value mean difference of log titer measurements.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data are shown in the manuscript ﬁgures and supplementary information. All the
data generated in this study are provided in the Source Data ﬁle
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Lentivirus pseudovirion neutralization assay. Antibody preparations were
evaluated by a qualiﬁed SARS-CoV-2 pseudovirus neutralization assay (PsVNA)
using WA1 strain and VOCs: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta
(B.1.617.2), and Omicron (B.1.1.529) (Supplementary Table S3). The PsVNA using
293-ACE2-TMPRSS2 cell line was described previously18,21. SARS-CoV-2 neutralizing activity measured by pseudovirion neutralization assay (PsVNA) correlated with PRNT (plaque reduction neutralization test with authentic SARS-CoV-2
virus) in previous studies17,18.
Brieﬂy, human codon-optimized cDNA encoding SARS-CoV-2 S glycoprotein
of the WA-1 or the VOCs was synthesized by GenScript and cloned into eukaryotic
cell expression vector pcDNA 3.1, between the BamHI and XhoI sites.
Pseudovirions were produced by co-transfection Lenti‐X‐ 293T cells with
psPAX2(gag/pol), pTrip-luc lentiviral vector, and pcDNA 3.1 SARS-CoV-2-spikedeltaC19/spike plasmid of VOC, using Lipofectamine 3000. The supernatants were.
harvested at 48 h post transfection, ﬁltered through 0.45 µm membranes, and
titrated using 293T-ACE2-TMPRSS2 cells (HEK 293T cells that express ACE2 and
TMPRSS2 proteins)34.
Neutralization assays were performed as previously described21,35. For the
neutralization assay, 50 µL of SARS-CoV-2 S pseudovirions (counting ~200,000
relative light units) were pre-incubated with an equal volume of medium
containing serial dilutions (20−, 60−, 180−, 540−, 1,620−, 4,860−, 14,580−, and
43,740-fold dilution at the ﬁnal concentration) of heat-inactivated serum at room
temperature for 1 h. Then 50 µL of virus-antibody mixtures were added to 293TACE2-TMPRSS2 cells (104 cells/50 μL)34 in a 96-well plate. The input virus with all
SARS-CoV-2 strains used in the current study were the same (2 × 105 relative light
units/50 µL/well). After a 3 h incubation, fresh medium was added to the wells.
Cells were lysed 24 h later, and luciferase activity was measured using One-Glo
luciferase assay system (Promega, Cat# E6130). The assay of each serum was
performed in duplicate, and the 50% neutralization titer was calculated using Prism
9 (GraphPad Software).
The PsVNA is a qualiﬁed assay where all samples are run with set of internal
standards in every plate and conforms with assay performance. Evaluation of
serum or plasma (collected with various anticoagulants: sodium heparin, lithium
heparin, and EDTA), and other body ﬂuids demonstrated no impact of sample
matrix type in the neutralization assay. Samples were fresh and not freeze-thawed.
Controls included cells only, viruses without any antibody and positive sera. The
limit of detection for the neutralization assay is 1:20. We did not observe any batch
effects as variations for replicates within the assays are <7% for PsVN assays.
Seroreactivity of post-vaccination samples to SARS-CoV-2 nucleocapsid by
ELISA. 96-well Immulon plates were coated with 50 ng/100 µL of recombinant
nucleocapsid from WA1/2020 in PBS overnight at 4oC. Starting at a 1:20 dilution,
serum samples were serially diluted 5-fold and applied to the coated well for 1 hr at
ambient temperature. Serum samples were assayed in duplicate. After three washes
8
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